206 related articles for article (PubMed ID: 27239089)
21. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.
Yu XW; Wu TY; Yi X; Ren WP; Zhou ZB; Sun YQ; Zhang CQ
Tumour Biol; 2014 Jan; 35(1):155-60. PubMed ID: 23907576
[TBL] [Abstract][Full Text] [Related]
22. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
23. A guardian turned rogue: TP53 promoter translocations rewire stress responses to oncogenic effectors in osteosarcoma.
Herold N
Cancer Gene Ther; 2024 Jun; 31(6):805-806. PubMed ID: 38409586
[TBL] [Abstract][Full Text] [Related]
24. Clinical and Molecular Analysis of Pathologic Fracture-associated Osteosarcoma: MicroRNA profile Is Different and Correlates with Prognosis.
Lozano Calderón SA; Garbutt C; Kim J; Lietz CE; Chen YL; Bernstein K; Chebib I; Nielsen GP; Deshpande V; Rubio R; Wang YE; Quackenbush J; Delaney T; Raskin K; Schwab J; Cote G; Spentzos D
Clin Orthop Relat Res; 2019 Sep; 477(9):2114-2126. PubMed ID: 31389890
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of microRNAs in osteosarcoma: A meta-analysis.
Kim YH; Goh TS; Lee CS; Oh SO; Kim JI; Jeung SH; Pak K
Oncotarget; 2017 Jan; 8(5):8726-8737. PubMed ID: 28060730
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
27. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
Omura G; Ando M; Ebihara Y; Saito Y; Kobayashi K; Fukuoka O; Akashi K; Yoshida M; Asakage T; Yamasoba T
BMC Cancer; 2017 Dec; 17(1):898. PubMed ID: 29282038
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis.
Ren W; Gu G
Eur J Cancer Care (Engl); 2017 Jan; 26(1):. PubMed ID: 26503016
[TBL] [Abstract][Full Text] [Related]
30. Association between PTEN and clinical-pathological features of osteosarcoma.
Zhou J; Xiao X; Wang W; Luo Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31270249
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.
Qu JT; Wang M; He HL; Tang Y; Ye XJ
J Cancer Res Clin Oncol; 2012 May; 138(5):819-25. PubMed ID: 22274866
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic significance and prognostic value of circRNAs in osteosarcoma: a systematic review and meta-analysis.
Zhong J; Zhang G; Yao W
J Orthop Surg Res; 2021 Oct; 16(1):578. PubMed ID: 34620208
[TBL] [Abstract][Full Text] [Related]
34. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
[TBL] [Abstract][Full Text] [Related]
35. Malignant transformation of fibrous dysplasia into osteosarcoma confirmed with TP53 somatic mutation and mutational analysis of GNAS gene.
Yap FHX; Amanuel B; Van Vliet C; Thomas M; Wong D
Pathology; 2021 Aug; 53(5):652-654. PubMed ID: 33272697
[No Abstract] [Full Text] [Related]
36. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
37. [Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children].
Patiño García A; Sierrasesúmaga Ariznabarreta L
An Esp Pediatr; 1997 Nov; 47(5):478-82. PubMed ID: 9586287
[TBL] [Abstract][Full Text] [Related]
38. Genetic and clonal dissection of osteosarcoma progression and lung metastasis.
Xu H; Zhu X; Bao H; Wh Shek T; Huang Z; Wang Y; Wu X; Wu Y; Chang Z; Wu S; Tang Q; Zhang H; Han A; Mc Cheung K; Zou C; Yau R; Ho WY; Huang G; Batalha S; Lu J; Song G; Kang Y; Shao YW; Lam YL; Shen J; Wang J
Int J Cancer; 2018 Sep; 143(5):1134-1142. PubMed ID: 29569716
[TBL] [Abstract][Full Text] [Related]
39. P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.
Bu J; Li H; Liu LH; Ouyang YR; Guo HB; Li XY; Xiao T
Int J Clin Exp Pathol; 2014; 7(9):6091-6. PubMed ID: 25337256
[TBL] [Abstract][Full Text] [Related]
40. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
